Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Alzheimer's disease treatments delisted in France

According the Prescrire, a French medical journal, drug treatments for Alzheimer's disease have been delisted in France and will no longer be reimbursed by the national health insurance system.

According to the article, the National Authority for Health (HAS) has previously issued guidance recommended treatments including donepezil, galantamine, rivastigmine and memantine. A review in 2016 of the harm-benefit balance of these treatments by France's Pharmacoeconomic Committee resulted in HAS acknowledging that these drugs have no place in the management of Alzheimer's disease.

Current guidance from NICE still recommends these treatments as options along with a range of other interventions to promote wellbeing and functional ability.

Action: Clinicians should continue to follow current NICE guidance however this move represents an interesting move away from medication in favour of supportive strategies for daily living that includes assistance for caregivers and family members.

Share 'Alzheimer's disease treatments delisted in France' on Email Share 'Alzheimer's disease treatments delisted in France' on Delicious Share 'Alzheimer's disease treatments delisted in France' on Digg Share 'Alzheimer's disease treatments delisted in France' on Facebook Share 'Alzheimer's disease treatments delisted in France' on Google+ Share 'Alzheimer's disease treatments delisted in France' on reddit Share 'Alzheimer's disease treatments delisted in France' on StumbleUpon Share 'Alzheimer's disease treatments delisted in France' on Twitter

CKS Updates - July 2018

During July 2018 Clinical Knowledge Summaries were published or updated in the following areas.

New topics were published for:

The following topics were all reviewed:

The majority of topics have undergone reviews and minor restructures.

The most significant changes were to the Fungal skin infection - body and groin topic which has had new nodes on Definition, Risk factors, Prevalence, Complications, and Prognosis added to the Background information section. The Prescribing Information section has also been updated and expanded in line with current CKS style for this topic and the Osteoarthritis topic.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - July 2018' on Email Share 'CKS Updates - July 2018' on Delicious Share 'CKS Updates - July 2018' on Digg Share 'CKS Updates - July 2018' on Facebook Share 'CKS Updates - July 2018' on Google+ Share 'CKS Updates - July 2018' on reddit Share 'CKS Updates - July 2018' on StumbleUpon Share 'CKS Updates - July 2018' on Twitter

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer